Denali Therapeutics Inc.

Denali Therapeutics is a clinical-stage biopharmaceutical company developing barrier-crossing therapeutics for neurodegenerative and lysosomal storage diseases. Its core platform is designed to improve delivery of biologics across the blood-brain barrier, with lead programs including tividenofusp alfa for Hunter syndrome and DNL126 for Sanfilippo syndrome type A.

9.16

9.16

— Denali Therapeutics Inc.
%
Lead rare-disease therapeutics0% Clinical and pre-commercial biologic drug candidates for lysosomal storage diseases such as Hunter syndrome and Sanfilippo syndrome.
Neurodegenerative disease pipeline0% Programs targeting diseases including Alzheimer’s, Parkinson’s, and FTD using the company’s transport vehicle platform.
TV platform technology0% Barrier-crossing delivery technology intended to transport biotherapeutics into the brain and throughout the body.
Collaboration and license revenue100% Revenue from partnering arrangements, milestones, option fees, and other collaboration-related payments.

Denali does not yet sell approved products, so its current economic counterparties are collaboration partners rather...

  • Pharmaceutical collaboration partnersprimary

    Takeda, Sanofi, and Biogen pay for partnered research, development, and potential milestone/royalty economics.

  • Rare disease patients and caregiversprimary

    Families affected by Hunter syndrome and Sanfilippo syndrome are the intended end users for lead programs.

  • Neurology and metabolic disease specialistssecondary

    Specialist physicians would diagnose, prescribe, and monitor treatment if Denali’s therapies are approved.

  • Healthcare payers and hospital systemssecondary

    Insurers and treatment centers would reimburse and administer approved therapies in commercial markets.

Denali is headquartered in South San Francisco, California, with additional operations in Salt Lake City, Utah and...

  • •Headquartered in South San Francisco, California
  • •Clinical manufacturing operations in Salt Lake City, Utah
  • •Additional location in Zurich, Switzerland
  • •Current business is U.S.-centric and R&D-driven
  • •Future commercialization would expand international exposure

Denali’s strategy is to use its TV platform to discover and develop barrier-crossing biologics, then convert that...

01
Commercialize tividenofusp alfashort-term

A first approved product would convert Denali from a pure R&D company into a commercial rare-disease franchise.

02
Build a second commercial brand with DNL126medium-term

A second launch would reduce dependence on a single asset and strengthen the rare-disease platform.

03
Validate the TV platform across multiple indicationsmedium-term

Clinical proof-of-concept in several programs would support broader partnering and pipeline expansion.

04
Internalize selected manufacturing capabilitiesmedium-term

In-house clinical manufacturing can improve speed, flexibility, and supply reliability as programs advance.

Denali remains a clinical-stage company with no approved products, so its value depends heavily on regulatory success,...

critical

Clinical-stage development risk

The company has not completed a pivotal trial or obtained marketing approval, so outcomes remain uncertain.

Scope
All pipeline programs
Materiality
high
high

Regulatory approval risk

Lead programs depend on FDA and potentially EMA review, including accelerated approval pathways.

Scope
Tividenofusp alfa, DNL126
Materiality
high
high

Capital and dilution risk

Persistent operating losses and negative cash flow require ongoing external funding.

Scope
Company-wide
Materiality
high
high

Manufacturing and supply chain risk

Denali relies on CDMOs for most supply and is still building internal capabilities.

Scope
Clinical and future commercial supply
Materiality
medium
medium

Partner concentration risk

Current revenue is tied to a small number of collaboration partners and agreements.

Scope
Takeda, Sanofi, Biogen
Materiality
medium
Collaboration revenue recognition
Can cause quarter-to-quarter volatility in reported revenue
R&D accrual estimates
Affects operating expenses and liabilities
Stock-based compensation
Increases non-cash operating expense and affects loss metrics
Lease accounting
Affects balance sheet leverage and operating expense presentation

FILANA THERAPEUTICS, INC.

FLNA · Pharmaceutical Preparations

COGNITION THERAPEUTICS INC

CGTX · Biological Products, (No Diagnostic Substances)

Monopar Therapeutics

MNPR · Pharmaceutical Preparations

Taysha Gene Therapies, Inc.

TSHA · Biological Products, (No Diagnostic Substances)

Zenas BioPharma, Inc.

ZBIO · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

: 28/04/2026